Drug
Pertuzumab/Trastuzumab/Hyaluronidase-zzxf clinical trials
Also written RG6264 and RO7198574.
- studies test it
- 12
- open now
- 3
- in phase 3
- 4
- first study started
- 2018
Keep track of what changes. Save the Pertuzumab/Trastuzumab/Hyaluronidase-zzxf studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 4 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 7
Hoffmann-La Roche (4) · National Cancer Institute (NCI) (1) · Latin American Cooperative Oncology Group (1) · MedSIR (1) · Mayo Clinic (1) · Genentech, Inc. (1) · Dana-Farber Cancer Institute (1) · Baylor Breast Care Center (1)
Often tested with
Tested in the same studies.
Atezolizumab (3) · Ado-Trastuzumab Emtansine (3) · Paclitaxel (3) · Pertuzumab (3) · Trastuzumab (3) · Trastuzumab deruxtecan (2) · Entrectinib (2) · Inavolisib (2)
Studies
Open first, then newest update. How each study uses Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as PH FDC SC
- The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06439693Written as Phesgo
- Correlation of Clinical Response to Pathologic Response in Patients With Early Breast CancerRecruitingPhase 2Baylor Breast Care CenterNCT05020860Written as Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
- Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT05256225Written as Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
- Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-BlockadeActive, not recruitingPhase 2Latin American Cooperative Oncology GroupNCT06068985Written as PHESGO
- Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate CancerCompletedPhase 2Mayo ClinicNCT05730712Written as Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
- PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast CancerActive, not recruitingPhase 2MedSIRNCT06172127Written as Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection
- A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast CancerCompletedPhase 3Hoffmann-La RocheNCT04024462Written as Pertuzumab and Trastuzumab FDC SC
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast CancerCompletedPhase 3Hoffmann-La RocheNCT05415215Written as Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Written as Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
- A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast CancerCompletedPhase 3Hoffmann-La RocheNCT03493854Written as FDC of Pertuzumab and Trastuzumab SC
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnEarly Phase 1OHSU Knight Cancer InstituteNCT05238831Written as Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Given in every arm · 5 — Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is usual care beside what is tested
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Written as Phesgo
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Written as PHESGO
- A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT05296798Written as Phesgo
- A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery SystemCompletedPhase 1Hoffmann-La RocheNCT05275010Written as Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
- A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast CancerCompletedPhase 2Hoffmann-La RocheNCT03674112Written as Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)